Bioequivalence studies are crucial in evaluating whether new drugs can match an approved one regarding pharmacological effects and clinical performance. These studies test if drugs, despite different dosage forms, share identical plasma concentration-time profiles. Three types of equivalence are central to these studies: chemical, pharmaceutical, and therapeutic. Chemical equivalence indicates that two or more drug products contain identical active ingredients in equal amounts. Pharmaceutical equivalence signifies that drug products share uniform strength, quality, purity, and content. Therapeutic equivalence, conversely, denotes that multiple drug products with the same active ingredient can control or mitigate a disease identically.
In vivo and in vitro bioequivalence studies are two key methodologies used. In vivo studies consider therapeutic margins, absorption characteristics, physicochemical properties, and potential bioavailability issues. These factors are essential for assessing oral immediate-release products and non-oral or modified-release drugs with systemic action. In contrast, in vitro studies employ comparative dissolution tests to examine an active ingredient's release from different drug products. Under specific conditions, such as when the product differs only in strength or is a solution or solubilized form, in vitro studies can substitute for their in vivo counterparts.
In summary, bioequivalence studies, whether in vivo or in vitro, ensure that a new drug's effectiveness matches that of an already approved drug.
Equivalence involves comparing drug products based on specific characteristics, functions, or a set of predefined standards. Equivalence can be of multiple types.
For example, chemical equivalence refers to two or more drug products containing equal quantities of identical active ingredients, while pharmaceutical equivalence implies sharing uniform strength, quality, purity, and content.
Therapeutic equivalence denotes that multiple drug products with the same active ingredient can control the disease identically.
Bioequivalence studies evaluate if a new drug mirrors an approved one in terms of pharmacological effects and clinical performance.
They test whether drugs in identical dosage forms share statistically similar plasma concentration-time profiles.
In vivo study needs are assessed based on therapeutic margin, absorption characteristics, physicochemical properties, and evidence of bioavailability issues.
In vitro bioequivalence studies use comparative dissolution tests to examine the release of an active ingredient from different drug products.
繁體中文
